Publication date: Aug 01, 2024
Anti-Spike IgG antibodies against SARS-CoV-2, which are elicited by vaccination and infection, are correlates of protection against infection with pre-Omicron variants. Whether this association can be generalized to infections with Omicron variants is unclear. We conducted a retrospective cohort study with 8457 blood donors in Tyrol, Austria, analyzing 15,340 anti-Spike IgG antibody measurements from March 2021 to December 2022 assessed by Abbott SARS-CoV-2 IgG II chemiluminescent microparticle immunoassay. Using a Bayesian joint model, we estimated antibody trajectories and adjusted hazard ratios for incident SARS-CoV-2 infection ascertained by self-report or seroconversion of anti-Nucleocapsid antibodies. At the time of their earliest available anti-Spike IgG antibody measurement (median November 23, 2021), participants had a median age of 46. 0 years (IQR 32. 8-55. 2), with 45. 3% being female, 41. 3% having a prior SARS-CoV-2 infection, and 75. 5% having received at least one dose of a COVID-19 vaccine. Among 6159 participants with endpoint data, 3700 incident SARS-CoV-2 infections with predominantly Omicron sublineages were recorded over a median of 8. 8 months (IQR 5. 7-12. 4). The age- and sex-adjusted hazard ratio for SARS-CoV-2 associated with having twice the anti-Spike IgG antibody titer was 0. 875 (95% credible interval 0. 868-0. 881) overall, 0. 842 (0. 827-0. 856) during 2021, and 0. 884 (0. 877-0. 891) during 2022 (all p
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | SARS-CoV-2 infection |
pathway | REACTOME | SARS-CoV-2 Infection |
disease | VO | vaccination |
disease | MESH | infection |
disease | IDO | blood |
disease | VO | report |
disease | MESH | seroconversion |
disease | VO | time |
disease | VO | dose |
disease | VO | COVID-19 vaccine |
disease | VO | Glycoprotein |